The effect of oral colchicine and vitamin K1 on bone metabolism in patients with diabetes mellitus: A post-hoc analysis of a 2 × 2 factorial randomized controlled trial with 18F-sodium fluoride positron emission tomography

作者：J. Bellinge, Marc Sim, Roslyn J. Francis, Sing Ching Lee, Dick C. Chan, Christian M. Girgis, Gerald F. Watts, Joshua R. Lewis, Carl Schultz · 发表于：Bone · 年份：2025 · DOI：10.1016/j.bone.2025.117492 · 被引用次数：2 · 研究领域：Vitamin K Research Studies、Parathyroid Disorders and Treatments、Vitamin C and Antioxidants Research

Purpose Diabetes mellitus (DM) confers an increased risk of fracture. Fracture risk stratification techniques are imperfect, and preventative therapies are sparse. We aimed to describe features associated with a dysfunctional bone metabolism determined by 18 F-Sodium Fluoride Positron Emission Tomography ( 18 F-NaF PET) in patients with DM and test the effects of vitamin K1 and colchicine therapy on vertebral 18 F-NaF activity. Methods This is a post-hoc analysis of a 2 × 2 factorial randomized double-blind placebo-controlled trial. Participants aged 50–80 with DM underwent 18 F-NaF PET/CT imaging at baseline, 3 months of therapy with vitamin K1 (10mg/daily) or placebo, and colchicine (0.5 mg/day) or placebo and repeat 18 F-NaF PET/CT. The 18 F-NaF vertebral mean standardized uptake value (SUVmean) and the CT estimated bone mineral density (BMD) (in Hounsfield units) was evaluated from thoracic vertebra . Results In total, 149 individuals (66.4 % male, mean age 65.5 ± 6.8 years) were included. Male sex (β −1.421, 95 % CI [−1.826, −1.016], p < 0.001), duration of DM in years (−0.021 [−0.039, −0.002], p = 0.030) and CT estimated vertebral BMD (0.011 [0.006, 0.015], p < 0.001) were independently associated with the SUVmean. The change in the SUVmean was similar between vitamin K1 or placebo groups (−0.07 ± 0.64 v 0.07 ± 0.69, p = 0.20). Participants receiving colchicine therapy had a greater reduction in the SUVmean, compared with placebo (−0.12 ± 0.72 v 0.11 ± 0.60, p = 0.039)....